1. IL-7 immunotherapy for progressive multifocal leukoencephalopathy in a patient with already controlled HIV-1 infection on antiretroviral therapy
- Author
-
Fabrice Bonneville, Stella Rousset, Guillaume Martin-Blondel, Pierre Delobel, Yassine Taoufik, Marie Guille, Catherine Mengelle, Service Maladies infectieuses et tropicales [CHU Toulouse], Pôle Inflammation, infection, immunologie et loco-moteur [CHU Toulouse] (Pôle I3LM Toulouse), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Service Neuroradiologie Diagnostique et Thérapeutique [CHU Toulouse], Pôle imagerie médicale [CHU Toulouse], Laboratoire Virologie [CHU Toulouse], Institut Fédératif de Biologie (IFB), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Pôle Biologie [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Immunologie des Maladies Virales et Autoimmunes (IMVA - U1184), Université Paris-Sud - Paris 11 (UP11)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de Physiopathologie Toulouse Purpan (CPTP), Université Toulouse III - Paul Sabatier (UT3), and Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
- Subjects
Oncology ,medicine.medical_specialty ,medicine.medical_treatment ,viruses ,MESH: Leukoencephalopathy, Progressive Multifocal / diet therapy ,Immunology ,Treatment outcome ,Human immunodeficiency virus (HIV) ,MESH: HIV Infections / complications ,MESH: HIV Infections / drug therapy ,medicine.disease_cause ,MESH: Magnetic Resonance Imaging ,Leukoencephalopathy ,MESH: HIV-1 / isolation & purification ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,Internal medicine ,medicine ,Immunology and Allergy ,MESH: Treatment Outcome ,MESH: Anti-Retroviral Agents / administration & dosage ,MESH: Humans ,MESH: Middle Aged ,medicine.diagnostic_test ,MESH: Plasma / virology ,business.industry ,MESH: Interleukin-7 / administration & dosage ,Progressive multifocal leukoencephalopathy ,virus diseases ,Magnetic resonance imaging ,Immunotherapy ,[SDV.IMM.IMM]Life Sciences [q-bio]/Immunology/Immunotherapy ,medicine.disease ,Antiretroviral therapy ,MESH: Immunotherapy / methods ,MESH: Immunologic Factors / administration & dosage ,Infectious Diseases ,[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology ,MESH: JC Virus / isolation & purification ,[SDV.IMM]Life Sciences [q-bio]/Immunology ,MESH: Brain / diagnostic imaging ,MESH: Brain / pathology ,business ,MESH: Viral Load ,Viral load ,MESH: Cerebrospinal Fluid / virology ,MESH: Female - Abstract
International audience; The incidence of progressive multifocal leukoencephalopathy (PML) among patients living with HIV (PML-HIV) decreased in the antiretroviral therapy (ART) era. JC virus (JCV) infection of the brain remains a devastating disease. Given the lack of drugs controlling JCV, initiation of ART and subsequent recovery of JCV-specific CD4+ and CD8+ T-cell immune responses remain the only therapeutic option. Although the 1-year survival rate increased from 10% to 50%, other strategies are required.
- Published
- 2019